Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 7, 2003, Pages 716-719

  Hall, Francis T ^a   Freeman, Jeremy L ^a   Asa, Sylvia L ^b   Jackson, David G ^c   Beasley, Nigel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EOSIN; HEMATOXYLIN; IODINE 131; MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; INFORMATION RETRIEVAL; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL INFORMATION; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; NECK; PAPILLARY CARCINOMA; POSTOPERATIVE PERIOD; STAINING; THYROID CARCINOMA; THYROIDECTOMY; TISSUE SECTION; TISSUE SLICE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, PAPILLARY; HUMANS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; MULTIVARIATE ANALYSIS; THYROID NEOPLASMS;

EID: 0037827152     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.7.716     Document Type: Article

References (25)

1. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996; 172:692-694.
2. Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg. 2002;128:825-828.
3. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
4. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978-996.
5. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164:658-661.
6. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid. Head Neck. 1996;18:127-132.
7. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res. 2001;7:462-468.
8. Beasley N, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 2002;62:1315-1320.
9. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
10. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20: 672-682.
11. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186-191.
12. Jussila L, Valtola R, Partanen TA, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58:1599-1604.
13. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999; 86:2406-2412.
14. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155:1967-1976.
15. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381-1390.
16. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98:769-778.
17. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-394.
18. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
19. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001;22:317-321.
20. Fox SB. Tumour angiogenesis and prognosis. Histopathology. 1997;30:294-301.
21. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/ vascular endothelial growth factor. Lab Invest. 2000;80:99-115.
22. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203-212.
23. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573-583.
24. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199-205.
25. He YL, Kozaki KI, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002;94:819-825.